The immune system is a major target for cancer treatments. Immune checkpoint inhibitors and CAR-T cell therapy can dramatically improve outcomes for many cancers. But for about 70% of patients, these therapies don’t work.
Medtech venture investment recovery continues, but startup M&A remains limited: Pitchbook
Dive Brief: Venture capital investment in medtech companies rose roughly 3% year over year to $3.3 billion in the second quarter, according to a new
September 4, 2024